Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;5(1):11-18.
doi: 10.1016/j.afos.2019.02.002. Epub 2019 Mar 14.

Effectiveness of monthly intravenous ibandronate injections in a real-world setting: Subgroup analysis of a postmarketing observational study

Yasuhiro Takeuchi  1 , Junko Hashimoto  2 , Hiroyuki Kakihata  3 , Yousuke Nishida  3 , Michiko Kumagai  3 , Chiemi Yamagiwa  3
Affiliations

Effectiveness of monthly intravenous ibandronate injections in a real-world setting: Subgroup analysis of a postmarketing observational study

Yasuhiro Takeuchi et al. Osteoporos Sarcopenia. 2019 Mar.

Abstract

Objectives: The favorable safety and consistent effectiveness of monthly intravenous (IV) ibandronate injections was demonstrated in a prospective, postmarketing, observational study in Japanese patients with osteoporosis. Here, we present subgroup analyses from the study.

Methods: Lumbar spine (L2-4) bone mineral density (BMD) gains were assessed in the following subgroups: aged <75 or ≥75 years, absence or presence of vertebral fractures, previous bisphosphonate (BP) treatment, and concomitant versus naïve osteoporosis drug treatment. The cumulative incidence of fractures and relative change in bone turnover markers were also examined.

Results: Of 1062 enrolled patients, 1025 received monthly IV ibandronate 1 mg and were assessed for 12 months. BMD gains with ibandronate were comparable, irrespective of older age or prevalent fractures. Overall, 515 patients (50.2%) had previously received osteoporosis treatment; of these, 166 (16.1%) received other BPs. Mean BMD changes were 3.69% (95% confidence interval [CI], 0.89%-6.50%) in patients previously treated with other BPs, and 4.26% (95% CI, 2.88%-5.64%) in patients who had not received prior osteoporosis treatment. Among the 510 patients (49.7%) concomitantly prescribed active vitamin D drugs, mean BMD changes were 5.74% (95% CI, 2.53%-8.95%) with eldecalcitol versus 3.54% (95% CI, 1.98%-5.10%) with ibandronate alone. The lowest fracture incidence was observed with the combination of ibandronate and eldecalcitol, but differences between the subgroups were not statistically significant.

Conclusions: Monthly IV ibandronate demonstrated comparable BMD gains in the patient subgroups analyzed. Concomitant use of ibandronate with eldecalcitol showed a trend of higher BMD gains and lower fracture incidence than ibandronate alone.

Keywords: Eldecalcitol; Ibandronate; Japan; Observational study; Osteoporosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Mean relative change in lumbar spine (L2–4) bone mineral density (BMD) from baseline to 12 months (with 95% confidence interval) in: (A) patients aged <75 versus ≥75 years; and (B) patients with versus without prevalent vertebral fractures.
Fig. 2
Fig. 2
Mean relative change in: (A) lumbar spine (L2–4) bone mineral density (BMD) and (B) tartrate-resistant acid phosphatase-5b (TRACP-5b) levels from baseline to 12 months (with 95% confidence intervals) in patient subgroups receiving no prior treatment, other bisphosphonates, or other osteoporosis treatment.
Fig. 3
Fig. 3
Mean relative change in: (A) lumbar spine (L2–4) bone mineral density (BMD) and (B) tartrate-resistant acid phosphatase-5b (TRACP-5b) levels from baseline to 12 months (with 95% confidence intervals) in patient subgroups receiving no concomitant vitamin D, concomitant eldecalcitol, or concomitant alfacalcidol or calcitriol.
Fig. 4
Fig. 4
Nonvertebral fracture incidence according to vitamin D drug treatment: (A) ibandronate alone versus ibandronate with concomitant eldecalcitol; (B) concomitant alfacalcidol or calcitriol versus concomitant eldecalcitol.
Fig. 5
Fig. 5
Clinical fracture incidence according to vitamin D drug treatment: (A) ibandronate alone versus ibandronate with concomitant eldecalcitol; (B) concomitant alfacalcidol or calcitriol versus concomitant eldecalcitol.
See this image and copyright information in PMC

References

    1. Reginster J.Y., Adami S., Lakatos P., Greenwald M., Stepan J.J., Silverman S.L. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;65:654–661. - PMC - PubMed
    1. Eisman J.A., Civitelli R., Adami S., Czerwinski E., Recknor C., Prince R. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008;35:488–497. - PubMed
    1. Miller P.D., Recker R.R., Reginster J.Y., Riis B.J., Czerwinski E., Masanauskaite D. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporos Int. 2012;23:1747–1756. - PubMed
    1. Bianchi G., Czerwinski E., Kenwright A., Burdeska A., Recker R.R., Felsenberg D. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporos Int. 2012;23:1769–1778. - PubMed
    1. Harris S.T., Blumentals W.A., Miller P.D. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin. 2008;24:237–245. - PubMed